Obesity Or Overweight clinical trials

Explore recruiting obesity or overweight clinical trials.

Recruiting obesity or overweight studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Obesity Or Overweight trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

J4M-MC-PWMP: A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants with Obesity or Overweight (ADVANCE) J4M-MC-PW01: Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral versus Placebo in Adolescent Participants Who Have Obesity, or Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)

Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

J2A-MC-GZPO: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Participants with Obesity or Overweight with and without Type 2 Diabetes. J2A-MC-GZP1: Participants with obesity or overweight with at least 1 weight-related comorbidity, without type 2 diabetes. J2A-MC-GZP2: Participants with obesity or overweight with type 2 diabetes

Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities

Germany, Belgium, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

J1I-MC-GZBJ: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1); J1I-MC-GOA1: Indication-Specific Appendix (ISA2) for participants with knee osteoarthritis (OA)

Romania, Poland, Hungary, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes

Hungary, Poland, Bulgaria, Germany, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Obesity Or Overweight trials by city

Obesity Or Overweight in Toronto Obesity Or Overweight in Vancouver Obesity Or Overweight in Montreal Obesity Or Overweight in Calgary Obesity Or Overweight in Edmonton Obesity Or Overweight in Ottawa Obesity Or Overweight in Winnipeg Obesity Or Overweight in Quebec City Obesity Or Overweight in Hamilton Obesity Or Overweight in Kitchener Obesity Or Overweight in London Obesity Or Overweight in Halifax Obesity Or Overweight in New York Obesity Or Overweight in Los Angeles Obesity Or Overweight in Chicago Obesity Or Overweight in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease